NR4A1 and breast carcinoma: Conversely, and consistent with our findings of a lesser role for the immune system in luminal breast cancer, a recent randomized trial in advanced hormone receptor-positive patients showed that the addition of the PD-1 antibody pembrolizumab to eribulin did not improve survival compared with eribulin alone [36].